Inj pegfilgrastim-bmez 0.5mg
Products billed under this code include Ziextenzo.
Payment limit per 0.5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Ziextenzo.
Payment limit per 0.5 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Ziextenzo | Sandoz Inc. | 61314-0866-01 | 12 | $3,626.964 |
| Ziextenzo | Sandoz Inc. | 61314-0866-02 | 12 | $3,626.964 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $302.247 | +$170.151 | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted September 17, 2026 |
| 3Q26 | $132.096 | +$12.459 | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted September 15, 2026 |
| 2Q26 | $119.637 | +$0.343 | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted September 15, 2026 |
| 1Q26 | $119.294 | +$88.971 | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted September 15, 2026 |
| 4Q25 | $30.323 | +$2.336 | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted September 8, 2026 |
| 3Q25 | $27.987 | +$3.276 | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted March 10, 2026 |
| 2Q25 | $24.711 | $0.00 | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted March 10, 2026 |
| 1Q25 | $24.711 | – | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted December 19, 2025 |
| 3Q23 | $30.049 | −$50.013 | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted June 5, 2024 |
| 2Q23 | $80.062 | −$9.88 | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted February 23, 2024 |
| 1Q23 | $89.942 | −$45.606 | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted December 6, 2023 |
| 4Q22 | $135.548 | −$18.589 | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted June 22, 2023 |
| 3Q22 | $154.137 | −$25.101 | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted June 9, 2023 |
| 2Q22 | $179.238 | −$43.623 | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted December 14, 2022 |
| 1Q22 | $222.861 | −$22.57 | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted June 8, 2022 |
| 4Q21 | $245.431 | −$25.129 | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted June 2, 2022 |
| 3Q21 | $270.56 | −$6.264 | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted June 2, 2022 |
| 2Q21 | $276.824 | −$21.138 | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted March 1, 2022 |
| 1Q21 | $297.962 | – | 0.5 MG | Inj pegfilgrastim-bmez 0.5mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.